[{"id":"2ef611e5-e4d2-495b-9d85-9c12e33be63b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02428543","created_at":"2021-01-18T11:37:05.675Z","updated_at":"2024-07-02T16:36:42.191Z","phase":"Phase 1/2","brief_title":"Ponatinib for FLT3-ITD Acute Myelogenous Leukemia","source_id_and_acronym":"NCT02428543","lead_sponsor":"Versailles Hospital","biomarkers":" FLT3 • NPM1 • WT1","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • FLT3 wild-type • NPM1 expression","tags":["FLT3 • NPM1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • FLT3 wild-type • NPM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2020-08-10"}]